Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall

Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says